STOCK TITAN

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary

Oramed Pharmaceuticals, focused on oral drug delivery systems, has announced it has enrolled over 50% of the 675 patients for its Phase 3 ORA-D-013-1 study of oral insulin capsule ORMD-0801 for type 2 diabetes. The study aims to compare the efficacy of ORMD-0801 to placebo over 6 to 12 months, assessing glycemic control via A1c levels. Concurrently, ORA-D-013-2 is enrolling 450 patients. Topline results are expected in 2022, positioning ORMD-0801 to potentially be the first commercial oral insulin for diabetes treatment.

Positive
  • Enrolled over 50% of patients in Phase 3 study ORA-D-013-1.
  • Potential to be the first oral insulin capsule for diabetes treatment.
  • Topline results expected in 2022.
Negative
  • None.

NEW YORK, June 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 50% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).  

Oramed Pharmaceuticals logo

ORA-D-013-1 is the larger of Oramed's two Phase 3 studies being conducted under U.S. Food and Drug Administration (FDA) approved protocols to treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months. The concurrent study, ORA-D-013-2, commenced enrollment in March for a planned 450 patients. Efficacy data for ORA-D-013-1 will become available after all patients have completed the first 6-month treatment period.

"As we continue on pace with randomization in the world's first Phase 3 oral insulin study conducted under an FDA approved protocol, we anticipate announcing topline results in 2022," said Oramed CEO Nadav Kidron.

About the Study

ORA-D-013-1 is recruiting 675 patients who are currently on 2 or 3 oral glucose-lowering agents through 75 clinical sites throughout the U.S. The primary endpoint of the study is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by A1c, with a secondary endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks. Efficacy data will become available after all patients have completed the first 6-month treatment period.

The ORA-D-013-1 trial is a double blind, double dummy study randomizing patients 1:1:1 for: 8 mg ORMD-0801 once-daily at night and placebo 45 minutes before breakfast; or 8 mg ORMD-0801 twice-daily at night and 45 minutes before breakfast; or placebo twice daily at night and 45 minutes before breakfast.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

For more information, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the pace of randomization and expected timing of topline results of our Phase 3 studies, the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes or revolutionizing the treatment of diabetes with our products. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact
Estee Yaari
+1-844-9-ORAMED
estee@oramed.com

Logo - https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg

 

 

Cision View original content:http://www.prnewswire.com/news-releases/oramed-reaches-50-enrollment-in-phase-3-oral-insulin-study-301307702.html

SOURCE Oramed Pharmaceuticals Inc.

FAQ

What is the ORA-D-013-1 study about?

The ORA-D-013-1 study is a Phase 3 clinical trial for Oramed's oral insulin capsule, ORMD-0801, aimed at treating type 2 diabetes.

How many patients are enrolled in ORA-D-013-1 study?

Oramed has enrolled over 50% of the 675 patients planned for the ORA-D-013-1 study.

When are the topline results for the ORA-D-013-1 study expected?

Topline results for the ORA-D-013-1 study are anticipated to be announced in 2022.

What are the primary endpoints of ORA-D-013-1?

The primary endpoint of the ORA-D-013-1 study is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by A1c levels.

What is the significance of the ORA-D-013-1 trial?

The trial is significant as it is the first Phase 3 oral insulin study conducted under FDA-approved protocols, potentially changing diabetes treatment.

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

ORMP Rankings

ORMP Latest News

ORMP Stock Data

98.76M
35.41M
10.52%
17.35%
0.72%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK